DNAPrint Genomics, Inc.: better drugs for segmented markets

Area of Science:

• Genomics and Bioinformatics
• Pharmacogenomics
• Drug Development

Background:

• The post-genomic era offers potential for more efficient drug development and targeted therapies.
• Current drug development faces challenges including high failure rates, litigation, and recalls.
• A need exists for novel models to improve drug efficacy and safety.

Purpose of the Study:

• To introduce a novel drug development model leveraging genomics and computational tools.
• To enhance the efficiency of clinical trials and improve post-market drug performance.
• To illustrate the viability of personalized medicine approaches in drug development.

Main Methods:

• Development and optimization of novel methods for assessing patient response proclivities.
• Utilizing a computational platform for modeling drug biology.
• Application of intelligence and new technologies for drug development.

Main Results:

• Established methods for assessing individual and population-based patient response.
• Developed a computational platform for drug biology modeling.
• Initiated engineering of select drug development projects to demonstrate the novel model.

Conclusions:

• The novel drug development model, based on intelligence and new technologies, shows promise for superior drug performance.
• Personalized medicine approaches can lead to improved patient outcomes and reduced drug development failures.
• This strategy aims to create targeted therapies for segmented markets, enhancing overall pharmaceutical effectiveness.